- ECJ issued a preliminary ruling on VAT reduction for Novo Nordisk
- Novo Nordisk tried to reduce VAT liability through corrected return based on payments to Hungary’s health insurance agency
- Background: Novo Nordisk submitted corrected VAT return, but was rejected by tax authority
- ECJ ruled that pharmaceutical companies can reduce taxable amount for payments to health insurance agency
- Taxable amount can be reduced by deducting price volume agreement payments
- Research and development expenses in health sector are also eligible for reduction
Source: globalvatcompliance.com
See also
- C-248/23 (Novo Nordisk) – Judgment – Reduction taxable amount on ex lege payments to the State health insurance agency
- Roadtrip through ECJ cases: Focus on Promotional activities/Discounts (Art. 79, 87, 90(1))
- C-462/16 – Boehringer Ingelheim Pharma GmbH & Co. KG – Discounts reduce the VAT value of pharmaceutical supplies
- C-717/19 – Boehringer Ingelheim – Reduction of the taxable amount – Agreement between pharmaceutical company and health insurer
- Join the Linkedin Group on ECJ VAT Cases, click HERE
- VATupdate.com – Your FREE source of information on ECJ VAT Cases
Click on the logo to visit the website
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
